financetom
Business
financetom
/
Business
/
Infosys accused by whistleblowers of 'unethical' practices to boost numbers, says report
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Infosys accused by whistleblowers of 'unethical' practices to boost numbers, says report
Oct 21, 2019 1:47 AM

Infosys has been accused of indulging in “unethical” practices to boost its short-term revenues and profits by a group comprising of anonymous employee of the IT giant describing themselves as “ethical employees.” The group has filed complaint with the Infosys board and the US Securities and Exchange Board (SEC), reported the Economic Times, adding that the whistleblowers have emails and voice recordings in evidence of their claims.

Infosys CEO Salil Parekh has been accused of bypassing reviews and approvals for large deals. “He (Parekh) directs them to make wrong assumptions to show margins,” the Economic Times quoted from the letter sent by the employees.

“CFO

Responding to the development, Infosys in a statement has said that it has placed the whistleblower complaint before its audit committee as per the company norms.

“The whistleblower complaint has been placed before the audit committee as per the company’s practice and will be dealt with in accordance with the company’s whistleblowers policy,” the statement said.

The whistleblowers' letter to the Infosys board was sent on September 20 while the one to the SEC is dates September 27, before a follow up on October 3.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PharmaCorp Rx up 10% as Announces Pharmacy Acquisition
PharmaCorp Rx up 10% as Announces Pharmacy Acquisition
May 25, 2026
11:14 AM EDT, 05/25/2026 (MT Newswires) -- PharmaCorp Rx (PCRX.V), up 10.4% on last look, is acquiring a PharmaChoice Canada-bannered pharmacy in Morrisburg, Ontario, for $8.2 million, the company said on Monday. PharmaCorp had executed letters of intent earlier this year regarding four additional pharmacy acquisitions. The Morrisburg pharmacy is the first conversion of the LOIs into a share purchase...
WonderFi Technologies Announces CIRO Approval for Acquisition by Robinhood; WonderFi Shares up 5.9%
WonderFi Technologies Announces CIRO Approval for Acquisition by Robinhood; WonderFi Shares up 5.9%
May 25, 2026
10:31 AM EDT, 05/25/2026 (MT Newswires) -- WonderFi Technologies' ( WONDF ) wholly-owned subsidiary, Coinsquare Capital Markets Ltd (CCML), received regulatory approval from the Canadian Investment Regulatory Organization (CIRO) for Robinhood Markets, Inc's previously announced acquisition of WonderFi ( WONDF ) pursuant to a statutory plan of arrangement under the Business Corporations Act (British Columbia), the company said on Monday....
Atlas Engineered Products Q1 Loss Widens
Atlas Engineered Products Q1 Loss Widens
May 25, 2026
10:39 AM EDT, 05/25/2026 (MT Newswires) -- Atlas Engineered Products ( APEUF ) , down 3% on last look, said on Monday that first-quarter net loss widened as revenue fell. Net loss for the quarter ended March 31, widened to $1.73 million, or $0.02 per diluted share, from a loss of $0.85 million, or $0.01 per diluted share, in the...
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
May 25, 2026
SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. ( IBRX ) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio ( IBRX ) securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved